Previous investigations have demonstrated that the attenuation of Ang II-infused proarrhythmic responses in AF can be achieved by targeting the oxidative loss of CaMKII in oxidation-resistant CaMKII MMVV murine models (42). The gene discussed is CAMK2G; the disease is atrial fibrillation.